599 related articles for article (PubMed ID: 27816756)
21. Controlling nutritional status score as a new indicator of overt hepatic encephalopathy in cirrhotic patients following transjugular intrahepatic portosystemic shunt.
Li J; Feng D; Pang N; Zhao C; Gao L; Liu S; Li L
Clin Nutr; 2022 Feb; 41(2):560-566. PubMed ID: 35032860
[TBL] [Abstract][Full Text] [Related]
22. Pre-transjugular intrahepatic portosystemic shunts (TIPS) prediction of post-TIPS overt hepatic encephalopathy: the critical flicker frequency is more accurate than psychometric tests.
Berlioux P; Robic MA; Poirson H; Métivier S; Otal P; Barret C; Lopez F; Péron JM; Vinel JP; Bureau C
Hepatology; 2014 Feb; 59(2):622-9. PubMed ID: 24620380
[TBL] [Abstract][Full Text] [Related]
23. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts.
Riggio O; Angeloni S; Salvatori FM; De Santis A; Cerini F; Farcomeni A; Attili AF; Merli M
Am J Gastroenterol; 2008 Nov; 103(11):2738-46. PubMed ID: 18775022
[TBL] [Abstract][Full Text] [Related]
24. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations.
Nolte W; Wiltfang J; Schindler C; Münke H; Unterberg K; Zumhasch U; Figulla HR; Werner G; Hartmann H; Ramadori G
Hepatology; 1998 Nov; 28(5):1215-25. PubMed ID: 9794904
[TBL] [Abstract][Full Text] [Related]
25. The improvement in body composition including subcutaneous and visceral fat reduces ammonia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.
Gioia S; Ridola L; Cristofaro L; Merli M; Faccioli J; Riggio O; Nardelli S
Liver Int; 2021 Dec; 41(12):2965-2973. PubMed ID: 34543504
[TBL] [Abstract][Full Text] [Related]
26. Sarcopenia is a risk factor for post-transjugular intrahepatic portosystemic shunt hepatic encephalopathy and mortality: A systematic review and meta-analysis.
Ahmed Z; Badal J; Gangwani MK; Nawaz A; Badal B; Arif SF; Farooq U; Kamal F; Javaid T; Aziz M; Lee-Smith W; Mahmood A; Merza N; Kobeissy A; Nawras A; Hassan M
Indian J Gastroenterol; 2023 Dec; ():. PubMed ID: 38085501
[TBL] [Abstract][Full Text] [Related]
27. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors.
Riggio O; Merlli M; Pedretti G; Servi R; Meddi P; Lionetti R; Rossi P; Bezzi M; Salvatori F; Ugolotti U; Fiaccadori F; Capocaccia L
Dig Dis Sci; 1996 Mar; 41(3):578-84. PubMed ID: 8617139
[TBL] [Abstract][Full Text] [Related]
28. Prediction of Mortality and Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Placement: Baseline and Longitudinal Body Composition Measurement.
Tuifua TS; Kapoor B; Partovi S; Shah SN; Bullen JA; Enders J; Laique S; Levitin A; Gadani S
J Vasc Interv Radiol; 2024 May; 35(5):648-657.e1. PubMed ID: 38244917
[TBL] [Abstract][Full Text] [Related]
29. Fat-free muscle mass in magnetic resonance imaging predicts acute-on-chronic liver failure and survival in decompensated cirrhosis.
Praktiknjo M; Book M; Luetkens J; Pohlmann A; Meyer C; Thomas D; Jansen C; Feist A; Chang J; Grimm J; Lehmann J; Strassburg CP; Abraldes JG; Kukuk G; Trebicka J
Hepatology; 2018 Mar; 67(3):1014-1026. PubMed ID: 29059469
[TBL] [Abstract][Full Text] [Related]
30. Low adipose tissue index as an indicator of hepatic encephalopathy in cirrhotic patients following transjugular intrahepatic portosystemic shunt.
Wang C; Teng Y; Gao J; Zhang Z; Li Y
Abdom Radiol (NY); 2023 Apr; 48(4):1454-1467. PubMed ID: 36735033
[TBL] [Abstract][Full Text] [Related]
31. Sarcopenia Does Not Worsen Survival in Patients With Cirrhosis Undergoing Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites.
Benmassaoud A; Roccarina D; Arico F; Leandro G; Yu B; Cheng F; Yu D; Patch D; Tsochatzis E
Am J Gastroenterol; 2020 Nov; 115(11):1911-1914. PubMed ID: 33156111
[TBL] [Abstract][Full Text] [Related]
32. Prediction of Patient Survival with Psoas Muscle Density Following Transjugular Intrahepatic Portosystemic Shunts: A Retrospective Cohort Study.
Zhang B; Cai W; Gao F; Lin X; Qian T; Gu K; Song B; Chen T
Med Sci Monit; 2022 Jan; 28():e934057. PubMed ID: 35031594
[TBL] [Abstract][Full Text] [Related]
33. Effects of transjugular intrahepatic portosystemic shunt on abdominal muscle mass in patients with decompensated cirrhosis.
Wu CH; Ho MC; Kao JH; Ho CM; Su TH; Hsu SJ; Huang HY; Lin CY; Liang PC
J Formos Med Assoc; 2023 Aug; 122(8):747-756. PubMed ID: 36868900
[TBL] [Abstract][Full Text] [Related]
34. Psoas Muscle Density in Combination with Model for End-Stage Liver Disease Score Can Improve Survival Predictability in Transjugular Intrahepatic Portosystemic Shunts.
Shoreibah MG; Mahmoud K; Aboueldahab NA; Vande Lune P; Massoud M; Bae S; El Khudari H; Gunn AJ; Abdel Aal AK
J Vasc Interv Radiol; 2019 Feb; 30(2):154-161. PubMed ID: 30717946
[TBL] [Abstract][Full Text] [Related]
35. Diabetes mellitus increases the risk of hepatic encephalopathy after a transjugular intrahepatic portosystemic shunt in cirrhotic patients.
Yin X; Zhang F; Xiao J; Wang Y; He Q; Zhu H; Leng X; Zou X; Zhang M; Zhuge Y
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1264-1269. PubMed ID: 31136318
[TBL] [Abstract][Full Text] [Related]
36. Early-Recurrent Overt Hepatic Encephalopathy Is Associated with Reduced Survival in Cirrhotic Patients after Transjugular Intrahepatic Portosystemic Shunt Creation.
Zuo L; Lv Y; Wang Q; Yin Z; Wang Z; He C; Guo W; Niu J; Bai W; Li K; Yu T; Yuan X; Chen H; Liu H; Xia D; Wang E; Luo B; Li X; Yuan J; Han N; Nie Y; Fan D; Han G
J Vasc Interv Radiol; 2019 Feb; 30(2):148-153.e2. PubMed ID: 30638778
[TBL] [Abstract][Full Text] [Related]
37. The Impact of Transjugular Intrahepatic Portosystemic Shunt on Nutrition in Liver Cirrhosis Patients: A Systematic Review.
Gazda J; Di Cola S; Lapenna L; Khan S; Merli M
Nutrients; 2023 Mar; 15(7):. PubMed ID: 37049459
[TBL] [Abstract][Full Text] [Related]
38. Proton Pump Inhibitor Use Is Associated with an Increased Frequency of New or Worsening Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation.
Lewis DS; Lee TH; Konanur M; Ziegler C; Hall MD; Pabon-Ramos WM; Suhocki PV; Smith TP; Kim CY; Choi SS; Ronald J
J Vasc Interv Radiol; 2019 Feb; 30(2):163-169. PubMed ID: 30638914
[TBL] [Abstract][Full Text] [Related]
39. Risk factors for overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation in patients with liver cirrhosis.
Tong H; Gan C; Wei B; Wang ZD; Li XD; Qian SJ; Huan H; Zhang LH; Yang Z; Chen YL; Gu YH; Chen LX; Yang YH; Wu H; Tang CW
J Dig Dis; 2021 Jan; 22(1):31-40. PubMed ID: 33128287
[TBL] [Abstract][Full Text] [Related]
40. Predicting disease progression in cirrhotic patients after transjugular intrahepatic portosystemic shunt implantation: A sex-stratified analysis.
Zhang Q; Long L; Zhu HL; Peng H; Luo XH; Zhu KS; Wang RP
World J Gastroenterol; 2023 Nov; 29(42):5768-5780. PubMed ID: 38075849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
